The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers
Author:
Publisher
Informa UK Limited
Subject
Oncology,Immunology,Immunology and Allergy
Link
http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1085148
Reference10 articles.
1. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
2. Kinome expression profiling and prognosis of basal breast cancers
3. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
5. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Expression of programmed death-ligand 1, IRF1 and CD8 T lymphocyte infiltration in a primary subset of breast cancer patients in Sudan;Journal of Taibah University Medical Sciences;2024-02
2. Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity;International Journal of Molecular Sciences;2023-10-10
3. IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment;International Immunopharmacology;2023-10
4. Qualitative analysis and numerical simulations of new model describing cancer;Journal of Computational and Applied Mathematics;2023-04
5. Aptamer-Based Strategies to Boost Immunotherapy in TNBC;Cancers;2023-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3